Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProgenaMatrix is a novel, advanced wound care product constructed from human keratin protein. It is the first and only commercially available human keratin matrix designed to assist in wound repair by providing a moist healing environment and supporting the body’s natural healing processes. The matrix is non-cellular, not tissue-based, resistant to degradation, and bio-inspired to activate both keratinocytes and fibroblasts while modulating immune response. Indicated for dry and exuding partial- and full-thickness wounds—including venous stasis ulcers, diabetic foot ulcers, pressure ulcers, burns (first- and second-degree), surgical wounds, donor sites/grafts—ProgenaMatrix offers an alternative to porcine or other tissue-based products with no cultural or religious barriers. It has FDA 510(k) clearance as a skin substitute device for wound management[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProgenaMatrix.